不同剂量的氯吡格雷治疗急性冠脉综合征的疗效及近期预后观察被引量：1

下载PDF

导出

摘要目的探讨急性冠脉综合征(ACS)患者使用不同剂量氯吡格雷治疗的疗效及近期预后.方法所有临床确定为ACS患者随机分为治疗组(n=80)和对照组(n=78),治疗组用常规治疗加首次负荷剂量氯吡格雷(波立维)300mg口服,随后两周每天150mg,之后每天口服75mg,对照组用常规治疗加波立维每天口服75mg,比较两组的疗效及近期预后.结果治疗组死亡、再梗死、中风、再发心绞痛、需要血运重建等联合终点事件治疗组与对照组分别为22.5%与41%,两组比较有显著性差异(P＜0.05);两组发生出血并发症比较无统计学意义(P＞0.05).结论给予负荷剂量且短期较大剂量使用氯吡格雷治疗ACS具有更好的疗效且安全,能改善ACS患者的近期预后.

作者任军蒋建东陆俊杰

机构地区宜兴市人民医院

出处《现代保健（医学创新研究）》 2006年第9期109-110,共2页

关键词急性冠脉综合征药物疗法预后氯吡格雷

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献9

1陈凌,郭若冰,戴军.氯吡格雷在缺血性心血管疾病防治中的作用[J].中国新药杂志,2000,9(10):718-721. 被引量：36
2[3]CAPRIE Steering Committee.Arandomized,Blinded,trial of clopidogrel versus aspirin in patients at risk of ischaemic events(CAPRIE)[J].Lancet,1996,348:1329～ 1339
3[4]CURE Study Investigators.Effects of Clopidogrel in Addition to Aspirin in Patients with Non-ST Elevation.Acute Coronary Syndromes[J].N Eng Med.August,2001,345:494 ～502.
4[5]CURE Study Investigators.Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.J Am Coll Cardiol,2005,45(6):838 ～45
5[6]Muller I,Besta F,Schulz C,et al.Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement[J].Thromb Haemost,2003,89 (5):783 ～ 787
6[7]Matetzky S,Shenkman B,Guetta V,et al.Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.Circulation,2004,109(25):3171 ～5
7[8]Müller I,Seyfarth M,Rudiger S,et al.Effect of a high dose of clopidogrel on platelet function in patients undergoing coronary stent placement[J].Heart,2001,85(1):92～93
8赵秀丽,胡大一.氯吡格雷[J].临床药物治疗杂志,2003,1(1):61-61. 被引量：8
9韩雅玲,王守力,李毅,荆全民,马颖艳,王祖禄,王冬梅,栾波,王效增.急性冠状动脉综合征患者冠状动脉支架术前高负荷量氯吡格雷预治疗近期疗效[J].中国介入心脏病学杂志,2005,13(1):9-12. 被引量：53

二级参考文献8

1Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002, 288: 2411-2420.
2Chart AW, Molitemo DJ, Berger PB, et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tiroffixan and ReoProGive Similar Ettlcacy Outcome Trial (TARGET). J Am CollCardiol, 2003,42:1188-1195.
3Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart, 2001,85:92-93.
4Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) TriM-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patient streated with recombinant tissue plasminogen activator and streptokinase.J Am Coil Cardiol, 1988,11:1-11.
5Biondi-Zoeeai GG, Agostoni P, Testa L, et al. Increased mortality after coronary stenting in patients treated with clopidogrel without loading dose. Evidence from a meta-analysis. Minerva Cardioangiol,2004,52:195-208.
6Kastrati A, Mehilli J, Schuhlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med, 2004,350:232-238.
7Pache J, Kastrati A, Mehilli J, et al. Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen.Catheter Cardiovasc Interv, 2002,55:436--441.
8Gawaz M, Seyfarth M, Muller I, et al. Comparison of effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. Am J Cardiol. 2001. 87 : 332-336.